Erectile dysfunction occurs following substantia nigra lesions in the rat
|
|
- Darcy Terry
- 6 years ago
- Views:
Transcription
1 (2001) 13, ß 2001 Nature Publishing Group All rights reserved /01 $ Erectile dysfunction occurs following substantia nigra lesions in the rat AR Zahran 1, N Simmerman 1, S Carrier 1 and P Vachon 1,2 * 1 Lady Davis Institute of the Jewish General Hospital, Department of Medicine, McGill University, Montreal, Quebec, Canada; and 2 MDS Pharma Services, Department of Metabolism and Animal Pharmacokinetics, Montreal, Quebec, Canada Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain. Behavioral apomorphine-induced penile erections were reduced (5=8) and increased (3=8) in uni- and bilateral lesioned animals. Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals. Lesions of the substantia nigra were confirmed by histology. Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats. Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson s disease. International Journal of Impotence Research (2001) 13, Keywords: rats; penile erection; apomorphine; intracavernous pressure; substantia nigra. Introduction James Parkinson first described idiopathic Parkinson s disease in 1817 as a neurodegenerative disorder with clinical signs such as bradykinesia, resting tremor, rigidity and postural imbalance. 1 The disease leads to progressive destruction of dopaminergic neurons that transport dopamine (DA) from the substantia nigra (SN) via the nigro-stiatal tract to the striatum and clinical signs of the disease appears when striatial DA is severely reduced. 2 Erectile dysfunction is a common problem in men with Parkinson s disease Pharmacological agents activating dopaminergic neurons via the D2 receptors have been shown to induce sexual responses and penile erections in animals and humans No animal model has been validated to study the pathophysiology of erectile dysfunction in Parkinson s disease and offer a better understanding of the effects of medications to treat Parkinson s disease on erectile function. The objective of the present study is to evaluate erectile function following lesions of the SN using injections of 6-hydroxydopamine (6-OH-DA) which mimic Parkinson s disease by destroying dopaminergic SN cells. 6-OH-DA was the first agent that had *Correspondence: P Vachon, Metabolism and Animal Pharmacokinetics, MDS Pharma Services, Ville St-Laurent, Montreal, Canada, H4R 2N6. Received 13 November 2000; accepted 4 May 2001 specific neurotoxic properties in the cathecolaminergic nervous system. 15 Injections of 6-OH-DA in the posterior hypothalamic regions cause severe neurobehavioral disturbances 16,17 producting prominent hypokinesia and tremor in rats. Specificity is achieved by using known stereotaxic coordinates targeting 6-OH-DA to the SN, the ventral tegmental area, the nigro-striatial tract, or the striatum. 18 Intrahypothalamic lesions provide the closest resemblance to the human disease in terms of behavioral manifestations and pharmacological responsiveness. To test our hypothesis, 6-OH-DA (experimental rats) and saline (control rats) were injected in the SN vicinity. Six weeks following surgery, erectile function was evaluated by behavioral apomorphineinduced penile erections and electrical stimulation of the cavernous nerve. Histological preparations, using the Klüver-Barrera staining method, were done to confirm lesions in the SN. Contents of DA and its metabolites, homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC), were evaluated in the cerebral hemispheres of all rats by high performance liquid chromatography (HPLC). Materials and methods Eighteen male Sprague Dawley rats (Charles River, Canada) weighing between 250 and 300 g were used in this study. They were kept in a standard laboratory animal environment (15 air changes=h,
2 256 temperature: 21 3 C, humidity: 40 60%, and light dark cycle: 12:12 h). They were housed in groups of two or three, in polycarbonate cages with treated pine shavings as bedding. Rats received fresh tap water daily and commercial laboratory rat food (Charles River, 5075 Rodent chow) ad libitum. Rats were kept in the animal facility of the Lady Davis Institute for Medical Research, Montreal Jewish General Hospital, which is accredited by the Canadian Council of Animal Care. The Institutional Animal Care and Use Committee prior to animal use approved the experimental protocol. Rats were anesthetized with an intraperitoneal dose of pentobarbital (50 mg=kg) (Somnotol, MTC Pharmaceuticals, Cambridge, Ontario, Canada) and positioned in a stereotaxic apparatus for 6-OH-DA injections. A midline incision of the skin of the skull was performed to expose bregma. A 1 mm trepanation was performed 5 mm posterior to bregma, 2 mm lateral to the midline and 8 mm ventral to the dura mater according to a previously established method. 15 A 6-OH-DA hydrobromide (Sigma, St Louis, MO, USA) solution (6.5 mg in3ml 0.9% saline containing 0.04% ascorbic acid; ph ) was injected using a 10 ml Hamilton syringe (Hamilton, Reno, NV, USA) immediately following preparation to minimize oxidation. Total injection time was 5 min, the needle was left in place for another 5 min. Bilateral 6-OH-DA animals were first injected in the vicinity of the right SN, immediately followed by the left SN. Unilateral 6-OH-DA animals were injected in the vicinity of the right SN only. Total surgical time, following anesthesia induction, did not exceed 30 min for both unilateral and bilateral cerebral hemisphere injected animals. Buprenorphine (0.01 mg=kg s.c.), a long acting opioid analgesic, was administered immediately prior to surgical procedures and 12 h post-surgery. Controls (n ¼ 5) consisted of sham operated agematched Sprague Dawley rats with bilateral stereotaxic injections of 0.9% saline containing 0.04% ascorbic acid in the same brain coordinates as experimental animals. The same surgical and postoperative procedures used in experimental rats were performed in the control rats. Six weeks after surgery, behavioral apomorphine-induced erections and cavernous nerve stimulation as well as HPLC assays, for brain DA and its metabolites, were performed. Six weeks following surgery, rats were acclimatized one-by-one to a custom built Plexiglas box in a semi-light room on three consecutive days for a period of 30 min. On the fourth day, they received 80 mg=kg of apomorphine subcutaneously (apomorphine hydrochloride, Sigma, St Louis, MO, USA) and filmed for 30 min with a home video camera using a mirror angled at 45 localized underneath the rats according to a previously described protocol. 19 Videos were subsequently viewed and the number of erections following apomorphine injections were counted. No other animal or personnel was present in the room for the 3 days of acclimation and for the erectile induction with apomorphine. Intracavernous pressure (ICP) measurements were done as previously published. 20 An initial intraperitoneal dose of 50 mg=kg pentobarbital (Somnotol, MTC Pharmaceuticals, Cambridge, Ontario, Canada) and subsequent quarter doses were given upon awakening to maintain the level of anesthesia throughout the experiments. Following a lower abdominal midline incision, the cavernous nerve and the crus of the corpus cavernosum were exposed and identified. A 23G needle coupled to PE-50 tubing was inserted in the corpus cavernosum. Cannulations were connected through a heparin-saline solution (250 IU=ml; Leo Laboratories, Ajax, Ontario, Canada) to pressure transducers (Abbott, Chicago, IL, USA). The signal was amplified (transducer amplifier model eth-200, AD Instruments, Castle Hill, Australia) and processed through MacLab 8S (AD Instruments, Castle Hill, Australia). Electrostimulation of the cavernous nerve was performed with stainless-steel bipolar hook electrodes. Monophasic rectangular pulses were delivered by a signal generator with constant current amplifier (MacLab Electrostimulator). Stimulus parameters were 2.0 ma, 20 Hz frequency, 0.2 ms pulse width and a duration of 1 min. At the end of each experiment and under deep anesthesia, animals were perfused with a saline solution (0.9% NaCl). Brains were rapidly removed from the cranium and immersed in 750 C solution. Sections were made at the injection site for histological controls. Sections (30 mm) were stained with the method of Klüver-Barrera to evaluate neuron loss in the SN. The striatum was removed and DA as well as major metabolite (HVA and DOPAC) concentrations were measured as previously described. 21 DA and its metabolites were analyzed using a Waters 600- MS HPLC (Waters, Canada) equipped with a mm Novapak C 18 column (Waters, Canada). The striatum from each cerebral hemisphere were weighed and analyzed for all rats. DA and its metabolites are reported as pmol=mg wet weight of striatal tissue. Standard concentration curves were established for DA and its metabolites prior to brain tissue evaluations. Statistical analysis was performed using a Student t-test. Statistical significance level was set a priori at P < Data in text and tables is expressed as mean s.d. Results Results showing the number of erections following subcutaneous apomorphine are shown in Table 1. Two types of behavior were clearly seen in uni-
3 Table 1 Sexual and motor behaviors following subcutaneous apomorphine injections 257 Groups No. animals WC a Average number of erections b (no. animals) Bilateral 6-OH-DA injections & (5 and 3) Unilateral 6-OH-DA injections & (3 and 2) Saline injection controls (5) a Number of animals presenting whole body circling (WC) following subcutaneous apomorphine injections. b Reported as sexual activity measured as the average number of apomorphine-induced erections with the corresponding number of animals in each category in parentheses. lateral and bilateral 6-OH-DA injected animals. Following apomorphine some animals (5=8) in both unilateral and bilateral injected 6-OH-DA rats had a decrease in the number of erections compared to normal rats (P < 0.01). Whereas in other animals (3=8), the average number of erections were increased following 6-OH-DA injections (P < 0.01). The number of erections in control rats following apomorphine injections was used as a basis of comparison. In both uni- and bilateral injected animals approximately 50% of the rats presented whole body circling following subcutaneous apomorphine. This is not surprising since clinical signs appear when striatal DA is reduced by 80% 2 and that although all animals had a significant decrease in DA levels this decrease was less than 80% for some animals. Mean peak intracavernous pressure was cm H 2 O in control rats following cavernous nerve stimulation whereas increases of and cm H 2 O(P < 0.001) were recorded in unilateral and bilateral lesioned rats, respectively. An example of SN cell loss following an injection of 6-OH-DA is shown in Figure 1. The destruction of the nigro-striatal pathway responsible for the Parkinson s syndrome occurs when the pars compacta of the SN is affected. Figure 1 shows a massive destruction of pars compacta and a less important loss of cells in the pars reticulata of the SN. Table 2 shows the concentrations of DA and its metabolites, DOPAC and HVA, from both right and left cerebral hemispheres. In unilateral 6-OH-DA injected rats only the right cerebral hemisphere shows a significant decrease in DA and its metabolites compared to controls. In bilateral 6-OH-DA injected rats, both hemispheres show a decrease of DA and its metabolites, however the left side of the brain is less affected than the right side. Discussion Results show that penile function is altered in rats following a decrease in DA content of the striatum with unilateral and bilateral 6-OH-DA intracerebral injections in the SN. Following 6-OH-DA injections, the number of apomorphine-induced erections were Figure 1 Microphotographs of a sagittal section of a unilateral 6- OH-DA injected rat brain showing a decrease in substantia nigra (SN) cells. (A) Normal SN from the contralateral side of the 6-OH- DA injection. (B) SN from the 6-OH-DA injected side. Note the almost complete absence of SN pars compacta (PC) neurons and the important accumulation of microglia at the injection site (arrowhead). A lesser number of neurons in the SN pars reticulata (PR) are also observed in the immediate vicinity of the injection site (Klüver-Barrera stain, magnification 6 100). decreased in 62% of the animals (8=13) and increased for 38% (5=13) of the animals. Penile intracavernous pressure was decreased in unilateral and bilateral lesioned animals following electrical stimulation of the cavernous nerve. Therefore central and peripheral effects on erectile mechanisms
4 258 Table 2 Left and right cerebral striatum concentrations of dopamine and dopamine metabolites measured by HPLC Left cerebral striatum concentrations (pmol=mg) Right cerebral striatum concentrations (pmol=mg) Dopamine DOPAC a HVA b Dopamine DOPAC a HVA b Control rats (n ¼ 5) c Bilateral injected rats (n ¼ 6) d ** * * *** *** ** Unilateral injected rats (n ¼ 3) d *** ** ** a Dihydroxyphenylacetic acid; b Homovanilic acid; c Stereotaxic saline injections in substantia nigra coordinates; d Stereotaxic injections of 6-OH-DA in substantia nigra coordinates. ***P < 0.001; **P < 0.01; *P < were observed following 6-OH-DA injections. Animals for which apomorphine-induced erections were increased could be partly explained by hypersensitivity of central receptor observed following denervation lesions, which may compensate for the loss of DA neurons. This could be accomplished by a decrease of DA autoreceptors and=or an increase in post-synaptic DA receptors. 22 The erectile hypersensitivity response could also be responsible for hypersexuality that has been observed following the administration of dopaminergic drugs in some Parkinson s patients. 23 However no study has clearly established the effects of dopaminergic-like drugs on the penile erection with respect to the duration of the disease or the extent of the SN lesion. The 6-OH-DA lesions and subsequent destruction of cells in the SN was confirmed by histology and the measurement of DA, and its metabolites in the striatum in corresponding lesioned hemispheres. The unilateral and bilateral lesions were performed since clinical signs in Parkinson s disease patients are mainly unilateral in the first stages of the disease and become bilateral in the later stages. 24 It is also recognized that the right hemisphere is dominant for sexual function EEG studies in normal men show that there is greater activation of the right cerebral hemisphere during periods of nocturnal penile tumescence. Stroke and lesions in the limbic system are associated with sexual dysfunction when the right cerebral hemisphere is affected. 28,29 Therefore, the right cerebral hemisphere seems dominant for penile erection. Our results show that the left hemisphere was less affected than the right hemisphere in bilateral injected 6-OH-DA animals. Since 6-OH-DA was first injected in the right hemisphere and the fact that 6-OH-DA is easily oxidized, it is likely that a delay of injection in the left hemisphere could explain the lower number of SN neurons being affected. However, compared to control animals, the DA content in the left striatum was 54% of controls and is still an appreciable decrease. Central dopaminergic mechanisms are involved in male sexual behavior. Apomorphine may restore erectile function in Parkinson s patients and in men suffering from psychogenic impotence. 30 Administration of DA agonists causes an increase in penile erections in rats. DA agonists injected in the medial preoptic area of the hypothalamus 31 and in the paraventricular nucleus (PVN) 11 regulates penile erection. The PVN could play a key role in penile erection since it receives projections from dopaminergic midbrain neurons and that efferent PVN projections mediate erection via oxytocin. 32 The PVN is also known to be important for yawning behavior and DA also seems to play a critical role since lesions of the PVN inhibit apomorphineinduced yawning in rats. 31 Interestingly SN lesions cause a decrease in apomorphine-induced yawning and these results are correlated with a decrease in DA and its metabolites in the striatum. 33 We also observed a decrease in ICP following electrical stimulation of the cavernous nerve. These results strongly suggest that a decrease in excitation from higher brain centers had an effect on peripheral mechanisms controlling penile erection. In this respect, although some SN lesioned rats had a greater number of erections following apomorphine administration, our results suggest that the quality of these erections may have been greatly diminished. A possible explanation for the observed peripheral effects could be that a decrease of DA afferent activity to the PVN would in turn decrease excitatory effects of oxytocin originating from the PVN onto the lumbar nuclei responsible for the motor control of erection. 34 A decrease of neuronal excitability onto lumbar neurons would also unbalance the inhibitory and facilitatory supraspinal descending controls causing inhibition of the lumbar nuclei responsible for erections. Both of these mechanisms could in turn down regulate the activity of NO fibers needed for erection and would be responsible for the observed decreased ICP response following cavernous nerve stimulations. SN is known to play a role in arterial blood pressure, however Turgut et al 35 have reported increases, and decreases, in mean arterial blood pressure ( 5mm Hg) in rats following 6-OH-DA lesions. Therefore, the change in arterial pressure following SN lesions is not sufficient to explain the decreased ICP
5 observed following cavernous nerve stimulation in the SN lesioned rats. The 6-OH-DA rat model of Parkinson s disease has been useful for the understanding of the pathophysiology and related pharmacology of the disease, however most studies show that it does not mimic the slow progressive dopaminergic neural degeneration seen in human patients. 36 However, Schwarting and Huston (1996) have shown that degeneration may be progressive in rats after 6-OH- DA administration. 37 Our results suggest that this model may be useful in understanding erectile dysfunction present in Parkinson s disease. Further work is needed to establish if the degenerative process evolves over time causing an erectile dysfunction in all animals injected with 6-OH-DA in the SN. Intracerebral injections of 6-OH-DA in the SN in rats caused erectile dysfunction. Behavioral apomorphine-induced penile erections were reduced in most uni- and bilateral 6-OH-DA lesioned animals. Intracavernous pressures following electrical stimulation of the cavernous nerve were decreased in these animals. Contents of DA and its metabolites, HVA and DOPAC, were decreased in the right cerebral striatum and the right and left cerebral striatum of the unilateral and bilateral 6-OH-DA lesioned rats, respectively. Measured parameters of penile dysfunction may therefore be related to a diminished DA brain content. Some animals showed an increase in the number of erections following apomorphine administration while intracavernous pressures were decreased and SN lesions were present. In these animals, striatal DA and its metabolites were also decreased. It is possible that receptor hypersensitivity in the central nervous system could be responsible for the increased sexual excitability following apomorphine injections. Acknowledgements This research project was supported by the Jewish General Foundation of the Montreal Jewish General Hospital. We greatly acknowledge Mme Jeanne Lavoie for histological preparations. We also wish to thank Dr Jane Montgomery and Ms Line Ste-Marie from the University of Montreal Hospital Research Center for the analysis of DA and metabolites by HPLC. References 1 Parkinson J. An essay on the shaking palsy. Whittingham and Roland: London, Tolwani RJ, et al. Experimental models of Parkinson s disease: insights from many models. Lab Anim Sci 1999; 49: Brown E, Brown GN, Kofman O, Quarrington B. Sexual function and affect in Parkinsonian men treated with L-dopa. Am J Psychiat 1978; 135: Koller WC et al. Sexual dysfunction in Parkinson s disease. Clin Neuropharmacol 1990; 13: Lipe H, Longstretch WT, Bird TD, Linde M. Sexuality and Parkinson s disease. Neurology 1989; 3: O Brien CP, Digiacomo JN, Fahn S, Schwarz GA. Mental effects of high-dosage Levodopa. Arch Gen Psychiat 1971; 24: Singer C, Sanchez-Ramos J, Weiner WJ, Ackerman M. Sexual dysfunction in Parkinsonian males. Neurology 1989; 3: Welsh M, Hung L, Waters CH. Sexuality in women with Parkinson s disease. Mov Dis 1997; 12: Wermuth L, Stenager E. Sexual aspects of Parkinson s disease. Seminars Neurol 1992; 12: Wermuth L, Stenager E. Sexual problems in young patients with Parkinson s disease. Acta Neurol Scand 1995; 91: Benassi-Benelli A, Ferrari F, Quarantotti BP. Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats. Arch Int Pharmacodyn Ther 1979; 242: Chen K-K, Chan JYH, Chang LK. Dopaminergic neurotransmission at the paraventricular nucleus of the hypothalamus in the central regulation of penile erection in the rat. J Urol 1999; 162: Heaton JP et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: Melis MR, Mauri A, Argiolas A. Apomorphine- and oxytocininduced penile erection and yawning in intact and castrated male rats: effect of sexual steroids. Neuroendocrinology 1994; 59: Ungerstedt U. 6-hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968; 5: Butterworth RF, Belanger F, Barbeau A. Hypokinesia produced by anterolateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugs. Pharmacol Biochem Behav 1978; 8: Rondeau DB, Jolicoeur FB, Belanger F, Barbeau A. Differential behavioral activities from anterior and posterior hypothalamic lesions in the rat. Pharmacol Biochem Behav 1998; 9: Perese DA et al. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 1989; 494: Carrier S et al. Age decreases nitric oxide synthase-containing nerve fibers in the rat penis. J Urol 1997; 157: Quinlan DM et al. The rat as a model for the study of penile erection. J Urol 1989; 141: Ste-Marie L, Boismenu D, Vachon L, Montgomery J. Evaluation of sodium 4-hydroxybenzoate as an hydroxyl radical trap using gas chromatography-mass spectrometry and high performance liquid chromatography with electrochemical detection. Anal Biochem 1996; 241: Kelly PH, Seviour PW, Iversen D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 1975; 94: Stern G, Lees A. Parkinson s disease. The Facts. Oxford University Press: Oxford, Cambier J, Masson M, Dehlen H. Syndromes parkinsoniens. In Masson SA (ed). Neurologie. Masson: Paris, 1985, pp Weinstein E. Effects of brain damage on sexual behavior. Med Asp Hum Sex 1981; 15: Coslett HB, Heilman KM. Male sexual function. Impairment after right cerebral hemisphere stoke. Arch Neurol 1986; 43: Hisrshkowitz M, Ware JC, Turner D. EEG amplitude asymmetry during sleep. Sleep Res 1979; 8: Coslett HB, Heilman KM. Male sexual function. Impairment after right cerebral hemisphere stroke. Arch Neurol 1986; 43: Weinstein E. Effects of brain damage on sexual behavior. Med Asp Hum Sex 1981; 15:
6 O Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson s disease. Mov Disord 1998; 13: Giuliano F et al. Stimulation of the medical preoptic area of the hypothalamus in the rat elicits increases in intracavernous pressure. Neurosoi Lett 1996; 209: Argiolas A, Melis MR, Mauri A, Gessa GL. Paraventricular nucleus lesion prevents yawning and penile erection induced by apomorphine and oxytocin by not by ACTH in rats. Brain Res 1987; 421: Laping NJ, Ramirez VD. Prolactin-induced yawning behavior requires an intact nigro-striatal dopamine system. Pharmacol Biochem Behav 1988; 29: Veronneau-Longueville F et al. Oxytocinergic innervation of autonomic nuclei controlling penile erection in the rat. Neuroscience 1999; 93: Turgut N et al. Asymetry of sympathetic activity in a rat model of Parkinson s disease induced by 6-hydroxydopamine: heamodynamic, electrocardiographic and biochemical changes. Res Exp Med 1998; 197: Bernheimer H, Birkmayer W, Hornykiewicz O. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: Schwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesions of the meso-striatal dopamine neurons and their physiological sequelea. Prog Neurobiol 1996; 49: Editorial Comment This manuscript tried to demonstrate an interesting animal model for deprivation of central dopamine. This animal model has the potential for advancing knowledge of the central mechanism of penile erection. However, this model may have a couple of questionable aspects. First, unfortunately, the results did not clearly show the relationship between the deprivation of dopamine and the number of erections following apomorphine injection. The authors divided the animals in the groups with bilateral and unilateral 6- OH-DA injections into two subgroups based on the average number of erections in the control group. Eight animals and five animals demonstrated higher and lower numbers of apomorphine-induced erections, respectively. There seems to be no correlation between the number of erections and deprivation of central dopamine. In addition, I do not think this method of data analysis is reasonable. Instead of such analysis, the average numbers of erections of all animals in each treatment group (ie bilateral or unilateral 6-OH-DA injections) are appropriate parameters to prove the authors hypothesis. The average values of the erections should then be compared with that of the control group statistically. If there is a significant difference, there is clear evidence that supports the authors hypothesis. Secondly, the animals injected with 6-OH-DA demonstrated a significantly lower ICP response following cavernous nerve stimulation. However, electrical stimulation of the cavernous nerve may not be a suitable stimulation method for the purpose of the authors, because the ICP response due to the cavernous nerve stimulation provides information about erectile conditions in peripheral systems (ie the peripheral nervous system and corporal smooth muscle, and peripheral vascular system). In other words, cavernous nerve stimulation can induce a normal ICP response, if the peripheral conditions are normal, even if disorders in the CNS exist. Therefore, for the authors purpose, measurement of ICP during electrical stimulation of the CNS (ie the MPOA, 1,2 or apomorphine-induced erectile response 3 are more suitable. To this end, this animal model that mimics Parkinson s disease may have potential, but more work and better analyses are needed for it to become a reliable animal model. References YSato 1 Giuliano F, Rampin O, Brown K, Courtois F, Benoit G, Jardin A. Stimulation of the medial preoptic area of the hypothalamus in the rat elicits increase in intracavernous pressure. Neurosci Lett 1996; 209: Sato Y, Christ JG. Differential ICP response elicited by electrical stimulation of the medial preoptic area. Am J Physiol 2000; 278: H964 H Anderson K-E, Gemalmaz H, Waldeck K, Chapman TN, Tuttle JB, Steers WD. The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat. J Urol 1999; 161:
The effect of sildenafil on electrostimulation-induced erection in the rat model
(2002) 14, 251 255 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The effect of sildenafil on electrostimulation-induced erection in the rat model N Ueno 1,
More informationLESIONS OF THE MESOLIMBIC DOPAMINE SYSTEM DISRUPT SIGNALLED ESCAPE RESPONSES IN THE RAT
ACTA NEUROBIOL: EXP. 1988, 48: 117-121 Short communication LESIONS OF THE MESOLIMBIC DOPAMINE SYSTEM DISRUPT SIGNALLED ESCAPE RESPONSES IN THE RAT W. Jeffrey WILSON and Jennifer C. HALL Department of Psychological
More informationLecture XIII. Brain Diseases I - Parkinsonism! Brain Diseases I!
Lecture XIII. Brain Diseases I - Parkinsonism! Bio 3411! Wednesday!! Lecture XIII. Brain Diseases - I.! 1! Brain Diseases I! NEUROSCIENCE 5 th ed! Page!!Figure!!Feature! 408 18.9 A!!Substantia Nigra in
More informationParkinson s disease (PD) is a neurodegenerative disorder that mainly affects individuals
Behavioral treatment of rotational behavior in the rat model of Parkinson s disease Parkinson s disease (PD) is a neurodegenerative disorder that mainly affects individuals 50 years and older. Degeneration
More informationVisualization and simulated animations of pathology and symptoms of Parkinson s disease
Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.
More informationBasal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota
Basal Ganglia Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Graduate School Discussion Wednesday, Nov 1, 11:00am MoosT 2-690 with Paul Mermelstein (invite your friends)
More informationDepartment of Urology, School of Medicine and Shu-Tien Urological Research Center, National Yang-Ming University, Taipei, Taiwan, Republic of China
(2002) 14, 139 145 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Involvement of L-arginine=nitric oxide pathway at the paraventricular nucleus of hypothalamus
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationTopical application of a Rho-kinase inhibitor in rats causes penile erection
(2004) 16, 294 298 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Topical application of a Rho-kinase inhibitor in rats causes penile erection Y Dai 1,2,3, K
More informationCOGNITIVE SCIENCE 107A. Motor Systems: Basal Ganglia. Jaime A. Pineda, Ph.D.
COGNITIVE SCIENCE 107A Motor Systems: Basal Ganglia Jaime A. Pineda, Ph.D. Two major descending s Pyramidal vs. extrapyramidal Motor cortex Pyramidal system Pathway for voluntary movement Most fibers originate
More informationReevaluation of levodopa therapy for the treatment of advanced Parkinson s disease
Parkinsonism and Related Disorders 15, Supplement 1 (2009) S25 S30 www.elsevier.com/locate/parkreldis Reevaluation of levodopa therapy for the treatment of advanced Parkinson s disease Masayuki Yokochi
More informationImpact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson s Disease
Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson s Disease FABIO G. TEIXEIRA,MIGUEL M.CARVALHO KRISHNA M. PANCHALINGAM ANA J.RODRIGUES
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. March 1, 2012 THE BASAL GANGLIA Objectives: 1. What are the main
More informationGreen Tea Polyphenol Epigallocatechin-3-Gallate Attenuates Behavioral Abnormality in Hemi-Parkinsonian Rat
Iranian Biomedical Journal 1 (4): 23-27 (October 26) Green Tea Polyphenol Epigallocatechin-3-Gallate Attenuates Behavioral Abnormality in Hemi-Parkinsonian Rat Tourandokht Baluchnejadmojarad *1 and Mehrdad
More information14 - Central Nervous System. The Brain Taft College Human Physiology
14 - Central Nervous System The Brain Taft College Human Physiology Development of the Brain The brain begins as a simple tube, a neural tube. The tube or chamber (ventricle) is filled with cerebrospinal
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. April 22, 2010 THE BASAL GANGLIA Objectives: 1. What are the
More informationHYPOTHALAMIC ELECTRICAL ACTIVITIES PRODUCED BY FACTORS CAUSING DISCHARGE OF PITUITARY HORMONES
HYPOTHALAMIC ELECTRICAL ACTIVITIES PRODUCED BY FACTORS CAUSING DISCHARGE OF PITUITARY HORMONES TERUO NAKAYAMA* Institute of Physiology, School of Medicine, University of Nagoya It is known that electrical
More informationhemiparkinsonism: dependence upon striatal
Journal of Neurology, Neurosurgery, and Psychiatry 1990;53:39-43 Department of Pharmacology, Karolinska institutet, Stockholm, Sweden M Herrera-Marschitz H Utsumi U Ungerstedt Correspondence to: Dr M Herrera-Marschitz,
More informationDopamine in Ube3a m-/p+ mice. Online Supplemental Material
Online Supplemental Material S1 Supplemental Figure 1. Schematic of rate-dependent intracranial self-stimulation (ICSS) (A) Mice implanted with monopolar stimulating electrodes to the medial forebrain
More informationBasal Ganglia General Info
Basal Ganglia General Info Neural clusters in peripheral nervous system are ganglia. In the central nervous system, they are called nuclei. Should be called Basal Nuclei but usually called Basal Ganglia.
More informationPSYCH 260 Exam 2. March 2, Answer the questions using the Scantron form. Name:
PSYCH 260 Exam 2 March 2, 2017 Answer the questions using the Scantron form. Name: 1 1 Main Please put in their proper order the steps that lead to synaptic communication between neurons. Begin with the
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationVL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements
BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.
More informationMaking Things Happen 2: Motor Disorders
Making Things Happen 2: Motor Disorders How Your Brain Works Prof. Jan Schnupp wschnupp@cityu.edu.hk HowYourBrainWorks.net On the Menu in This Lecture In the previous lecture we saw how motor cortex and
More informationDamage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.
Lecture 20 - Basal Ganglia Basal Ganglia (Nolte 5 th Ed pp 464) Damage to the basal ganglia produces involuntary movements. Although the basal ganglia do not influence LMN directly (to cause this involuntary
More informationTranscranial sonography in movement disorders
Transcranial sonography in movement disorders Uwe Walter 1st Residential Training of the European Society of Neurosonology and Cerebral Hemodynamics September 7-12, 2008 Bertinoro, Italy Department of
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationThe Parkinson s You Can t See
The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?
More informationThe motor regulator. 1) Basal ganglia/nucleus
The motor regulator 1) Basal ganglia/nucleus Neural structures involved in the control of movement Basal Ganglia - Components of the basal ganglia - Function of the basal ganglia - Connection and circuits
More informationDown regulation of the HCN2 channel in rat models of Parkinson s disease
Down regulation of the HCN2 channel in rat models of Parkinson s disease Abstract The basal ganglia is a key control centre involved with the regulation of movement. It is therefore a primary interest
More informationThe Brain Worksheet Sections 5-7
The Brain Worksheet Sections 5-7 1. neuroglia 2. autonomic nervous system 3. sensory neurons 4. oligodendrocytes 5. ascending tracts 6. descending tracts 7. saltatory propagation 8. continuous propagation
More informationBasal nuclei, cerebellum and movement
Basal nuclei, cerebellum and movement MSTN121 - Neurophysiology Session 9 Department of Myotherapy Basal Nuclei (Ganglia) Basal Nuclei (Ganglia) Role: Predict the effects of various actions, then make
More informationSurgical Treatment for Movement Disorders
Surgical Treatment for Movement Disorders Seth F Oliveria, MD PhD The Oregon Clinic Neurosurgery Director of Functional Neurosurgery: Providence Brain and Spine Institute Portland, OR Providence St Vincent
More informationExam 2 PSYC Fall (2 points) Match a brain structure that is located closest to the following portions of the ventricular system
Exam 2 PSYC 2022 Fall 1998 (2 points) What 2 nuclei are collectively called the striatum? (2 points) Match a brain structure that is located closest to the following portions of the ventricular system
More informationCNS MCQ 2 nd term. Select the best answer:
Select the best answer: CNS MCQ 2 nd term 1) Vestibular apparatus: a) Represent the auditory part of the labyrinth. b) May help in initiating the voluntary movements. c) Contains receptors concerned with
More informationDefined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several
Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several months and occurring at least half the time. Vinik
More informationChemical Control of Behavior and Brain 1 of 9
Chemical Control of Behavior and Brain 1 of 9 I) INTRO A) Nervous system discussed so far 1) Specific 2) Fast B) Other systems extended in space and time 1) Nonspecific 2) Slow C) Three components that
More informationAnatomy of the basal ganglia. Dana Cohen Gonda Brain Research Center, room 410
Anatomy of the basal ganglia Dana Cohen Gonda Brain Research Center, room 410 danacoh@gmail.com The basal ganglia The nuclei form a small minority of the brain s neuronal population. Little is known about
More informationTREATMENT-SPECIFIC ABNORMAL SYNAPTIC PLASTICITY IN EARLY PARKINSON S DISEASE
TREATMENT-SPECIFIC ABNORMAL SYNAPTIC PLASTICITY IN EARLY PARKINSON S DISEASE Angel Lago-Rodriguez 1, Binith Cheeran 2 and Miguel Fernández-Del-Olmo 3 1. Prism Lab, Behavioural Brain Sciences, School of
More informationThe neurvous system senses, interprets, and responds to changes in the environment. Two types of cells makes this possible:
NERVOUS SYSTEM The neurvous system senses, interprets, and responds to changes in the environment. Two types of cells makes this possible: the neuron and the supporting cells ("glial cells"). Neuron Neurons
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationBME 701 Examples of Biomedical Instrumentation. Hubert de Bruin Ph D, P Eng
BME 701 Examples of Biomedical Instrumentation Hubert de Bruin Ph D, P Eng 1 Instrumentation in Cardiology The major cellular components of the heart are: working muscle of the atria & ventricles specialized
More informationSee Policy CPT/HCPCS CODE section below for any prior authorization requirements
Effective Date: 1/1/2019 Section: SUR Policy No: 395 1/1/19 Medical Policy Committee Approved Date: 8/17; 2/18; 12/18 Medical Officer Date APPLIES TO: Medicare Only See Policy CPT/HCPCS CODE section below
More informationBASAL GANGLIA. Dr JAMILA EL MEDANY
BASAL GANGLIA Dr JAMILA EL MEDANY OBJECTIVES At the end of the lecture, the student should be able to: Define basal ganglia and enumerate its components. Enumerate parts of Corpus Striatum and their important
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Brown EN, Lydic R, Schiff ND, et al. General anesthesia, sleep,
More informationBasal ganglia Sujata Sofat, class of 2009
Basal ganglia Sujata Sofat, class of 2009 Basal ganglia Objectives Describe the function of the Basal Ganglia in movement Define the BG components and their locations Describe the motor loop of the BG
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationTHE CENTRAL NERVOUS SYSTEM. The Brain & Spinal Cord
THE CENTRAL NERVOUS SYSTEM The Brain & Spinal Cord Review: Nervous System Parallel Distributed Processing Composition of the CNS Nuclei: Clusters of neurons in the CNS ( neighborhoods ) Fiber Tracts/Pathways:
More informationBiological Bases of Behavior. 8: Control of Movement
Biological Bases of Behavior 8: Control of Movement m d Skeletal Muscle Movements of our body are accomplished by contraction of the skeletal muscles Flexion: contraction of a flexor muscle draws in a
More informationTeach-SHEET Basal Ganglia
Teach-SHEET Basal Ganglia Purves D, et al. Neuroscience, 5 th Ed., Sinauer Associates, 2012 Common organizational principles Basic Circuits or Loops: Motor loop concerned with learned movements (scaling
More informationBiological Bases of Behavior. 3: Structure of the Nervous System
Biological Bases of Behavior 3: Structure of the Nervous System Neuroanatomy Terms The neuraxis is an imaginary line drawn through the spinal cord up to the front of the brain Anatomical directions are
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationDeep Brain Stimulation: Surgical Process
Deep Brain Stimulation: Surgical Process Kia Shahlaie, MD, PhD Assistant Professor Bronte Endowed Chair in Epilepsy Research Director of Functional Neurosurgery Minimally Invasive Neurosurgery Department
More informationConnections of basal ganglia
Connections of basal ganglia Introduction The basal ganglia, or basal nuclei, are areas of subcortical grey matter that play a prominent role in modulating movement, as well as cognitive and emotional
More informationEffects of limbic corticostriatal lesions on a u t o shaping performance in rats
Effects of limbic corticostriatal lesions on a u t o shaping performance in rats BJ Everitt, JA Parkinson, G Lachenal, KM Halkerston, N Rudarakanchana, RN Cardinal, J Hall, CH Morrison, JW Dalley, SR Howes,
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationClasses of Neurotransmitters. Neurotransmitters
1 Drugs Outline 2 Neurotransmitters Agonists and Antagonists Cocaine & other dopamine agonists Alcohol & its effects / Marijuana & its effects Synthetic & Designer Drugs: Ecstasy 1 Classes of Neurotransmitters
More informationSpring balance evaluation of the ischiocavernosus muscle
International Journal of Impotence Research (2001) 13, 294 297 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Spring balance evaluation of the ischiocavernosus
More informationBasal Ganglia George R. Leichnetz, Ph.D.
Basal Ganglia George R. Leichnetz, Ph.D. OBJECTIVES 1. To understand the brain structures which constitute the basal ganglia, and their interconnections 2. To understand the consequences (clinical manifestations)
More informationFirst described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"
Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive
More informationbiological psychology, p. 40 The study of the nervous system, especially the brain. neuroscience, p. 40
biological psychology, p. 40 The specialized branch of psychology that studies the relationship between behavior and bodily processes and system; also called biopsychology or psychobiology. neuroscience,
More informationKinematic Modeling in Parkinson s Disease
Kinematic Modeling in Parkinson s Disease Alexander Hui Department of Bioengineering University of California, San Diego La Jolla, CA 92093 alexhui@ucsd.edu Abstract Parkinson s disease is a slowly progressing
More informationSupplementary Methods
1 Supplementary Methods Social Preference Test Subjects Seventy-four Long-Evans, male rats served as subjects (S-rats) in the foodpreference test, with 40 assigned to the CXT-Same (CXT-S) Condition and
More informationChapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.
Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationAnalysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease
Oxidative Stress laboratory Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease By Dr. Soliman Khatib Senior lecturer,
More informationSexual Interest and Neuroimaging of the Site of the Libido
Current Topics Organ Diseases and Autonomic Nervous System Juntendo Medical Journal 2016. 62(5), 381-385 Sexual Interest and Neuroimaging of the Site of the Libido AKIRA TSUJIMURA * *Department of Urology,
More informationThe Wonders of the Basal Ganglia
Basal Ganglia The Wonders of the Basal Ganglia by Mackenzie Breton and Laura Strong /// https://kin450- neurophysiology.wikispaces.com/basal+ganglia Introduction The basal ganglia are a group of nuclei
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationChapter 3. Structure and Function of the Nervous System. Copyright (c) Allyn and Bacon 2004
Chapter 3 Structure and Function of the Nervous System 1 Basic Features of the Nervous System Neuraxis: An imaginary line drawn through the center of the length of the central nervous system, from the
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationRecent Advances in Energy, Environment, Biology and Ecology
Acute and long-term effects elicited by psychoactive drugs on 50-kHz ultrasonic vocalizations in rats: development of a new experimental tool for the study of drug-mediated reward NICOLA SIMOLA Department
More informationSHORT ANSWER. Write the word or phrase that best completes each statement or answers the question.
Exam Name 1) A change in the conditions in the synaptic terminal can influence the soma as a result of axoplasmic transport. 2) The nervous system is composed of the brain and spinal cord. A) efferent
More informationCephalization. Nervous Systems Chapter 49 11/10/2013. Nervous systems consist of circuits of neurons and supporting cells
Nervous Systems Chapter 49 Cephalization Nervous systems consist of circuits of neurons and supporting cells Nervous system organization usually correlates with lifestyle Organization of the vertebrate
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationVAGAL INFLUENCE ON HEART RATE IN HIBERNATING GROUND SQUIRRELS
J. exp. Biol. 185, 25 32 (1993) Printed in Great Britain The Company of Biologists Limited 1993 25 VAGAL INFLUENCE ON HEART RATE IN HIBERNATING GROUND SQUIRRELS WILLIAM K. MILSOM Department of Zoology,
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationEFFECT OF HYPOTHALAMIC LESIONS ON PITUITARY MELANOCYTE-STIMULATING HORMONE
EFFECT OF HYPOTHALAMIC LESIO ON PITUITARY MELANOCYTE-STIMULATING HORMONE S. TALEISNIK, J. DE OLMOS, R. OR\l=I'\ASand MAR\l=I'\AE. TOMATIS Instituto de Investigación Médica, Mercedes y Martín Ferreyra*,
More information1. The cerebellum coordinates fine movement through interactions with the following motor-associated areas:
DENT/OBHS 131 2009 Take-home test 4 Week 6: Take-home test (2/11/09 close 2/18/09) 1. The cerebellum coordinates fine movement through interactions with the following motor-associated areas: Hypothalamus
More informationLevodopa vs. deep brain stimulation: computational models of treatments for Parkinson's disease
Levodopa vs. deep brain stimulation: computational models of treatments for Parkinson's disease Abstract Parkinson's disease (PD) is a neurodegenerative disease affecting the dopaminergic neurons of the
More informationBrain and behaviour (Wk 6 + 7)
Brain and behaviour (Wk 6 + 7) What is a neuron? What is the cell body? What is the axon? The basic building block of the nervous system, the individual nerve cell that receives, processes and transmits
More informationNsci 2100: Human Neuroanatomy 2017 Examination 3
Name KEY Lab Section Nsci 2100: Human Neuroanatomy 2017 Examination 3 On this page, write your name and lab section. On your bubble answer sheet, enter your name (last name, space, first name), internet
More informationThe Cerebral Cortex and Higher Intellectual Functions
The Cerebral Cortex and Higher Intellectual Functions Lobes in a lateral view of left hemisphere Atlas Fig.2-11 The Insula The Hidden Lobe Atlas Fig. 2-11 Atlas Fig. 2-39 Lobes in a lateral view of left
More informationMOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement
MOVEMENT 2 Dr. Steinmetz 3 OUTLINE The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement Parkinson s Disease Huntington s Disease 1 4 TYPES
More informationCourse Booklet. We have felt the pain that Neuroscience is giving you.
Exams Stressing You Out? Take Action! Course Booklet NEUR 1202 Carleton University* *TranscendFinals is not affiliated with the university We have felt the pain that Neuroscience is giving you. Our mission
More informationTitle: Restorative Effects of Uridine Plus Docosahexaenoic Acid in a Rat Model of Parkinson's Disease
Elsevier Editorial System(tm) for Neuroscience Research Manuscript Draft Manuscript Number: NSR-D-08-00172R1 Title: Restorative Effects of Uridine Plus Docosahexaenoic Acid in a Rat Model of Parkinson's
More informationNitric oxide (NO) and central dopamine (DA) D3 receptor reactivity to quinpirole in rats
Nitric oxide (NO) and central dopamine (DA) D3 receptor reactivity to quinpirole in rats Ryszard ~rusl, Ryszard szkilnik1 and Richard M. ~ostrzewa~ '~e~artment of Pharmacology, Silesian Academy of Medicine,
More informationAvailable online at
Journal of Basic and Clinical PATHOPHYSIOLOGY Available online at http://jbcp.shahed.ac.ir/ Volume 4, Number 1, Autumn-Winter 2015-2016 Malva sylvestris aqueous extract could ameliorate 6-hydroxydopamine-induced
More informationCitation 泌尿器科紀要 (1988), 34(7):
Title Can an intracavernous papaverine in arteriogenic impotence? Author(s) Imagawa, Akio; Kawanishi, Yasuo Citation 泌尿器科紀要 (1988), 34(7): 1185-1189 Issue Date 1988-07 URL http://hdl.handle.net/2433/119644
More informationDISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a
More informationSystems Neuroscience Dan Kiper. Today: Wolfger von der Behrens
Systems Neuroscience Dan Kiper Today: Wolfger von der Behrens wolfger@ini.ethz.ch 18.9.2018 Neurons Pyramidal neuron by Santiago Ramón y Cajal (1852-1934, Nobel prize with Camillo Golgi in 1906) Neurons
More informationDepartment of Neurology/Division of Anatomical Sciences
Spinal Cord I Lecture Outline and Objectives CNS/Head and Neck Sequence TOPIC: FACULTY: THE SPINAL CORD AND SPINAL NERVES, Part I Department of Neurology/Division of Anatomical Sciences LECTURE: Monday,
More informationEFFECTS OF AMYGDALOID LESIONS ON PLASMA AND PITUITARY LEVELS OF LUTEINIZING HORMONE IN THE MALE DEERMOUSE
EFFECTS OF AMYGDALOID LESIONS ON PLASMA AND PITUITARY LEVELS OF LUTEINIZING HORMONE IN THE MALE DEERMOUSE B. E. ELEFTHERIOU, A. J. ZOLOVICK and R. L. NORMAN Department of Zoology, Kansas State University,
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationUNDERSTANDING PARKINSON S DISEASE
UNDERSTANDING PARKINSON S DISEASE WHAT IS PARKINSON S DISEASE? A progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middleaged
More informationBrain Mechanisms of Emotion 1 of 6
Brain Mechanisms of Emotion 1 of 6 I. WHAT IS AN EMOTION? A. Three components (Oately & Jenkins, 1996) 1. caused by conscious or unconscious evaluation of an event as relevant to a goal that is important
More informationmetabolism inhibition, this approach causes other adverse effects. The dosage of L-dopa can be brought down further by co-medication of dopamine
6XPPDU\ Parkinson s disease is a serious neurological disorder of the central nervous system that usually becomes apparent after the age of 55. It concerns the increased deterioration of neurons responsible
More informationBrain dopamine and mild hypoxia
Brain dopamine and mild hypoxia Denoroy L, Orset C, Parrot S, Berod A, Sauvinet V, Cottet-Emard JM, Pequignot JM. Université Claude Bernard, Lyon, France Striatum vulnerable to hypoxia ischemia necrotic
More information